Douglas K. Marks
Impact in
-
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Cancer-related Molecular Pathways
-
- Immunotherapy and Immune Responses
Papers in
- Oncology 12
- Cancer Immunotherapy and Biomarkers 5
- CAR-T cell therapy research 3
-
- Metabolism, Diabetes, and Cancer 2
- Co-authors
- Stephen E. Goldstone (1 shared paper)Yvonne M. Saenger (9 shared papers)Robyn D. Gartrell (9 shared papers)Thomas D. Hart (6 shared papers)Basil A. Horst (6 shared papers)Bret Taback (5 shared papers)Emanuelle M. Rizk (4 shared papers)Evan Rosenbaum (1 shared paper)
- Journals
- Journal of Clinical Oncology (7 papers)Clinical Cancer Research (2 papers)Cancer Research (2 papers)Clinical Breast Cancer (1 paper)Blood (1 paper)
- Partner nations
- United StatesCanadaSwitzerland
In The Last Decade
Douglas K. Marks
25 papers receiving 313 citations
Peers
Comparison fields: 5 of 47
- Oncology 149
- Immunology 66
- Pulmonary and Respiratory Medicine 59
- Cancer Research 25
- Epidemiology 52
Countries citing papers authored by Douglas K. Marks
This map shows the geographic impact of Douglas K. Marks's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Douglas K. Marks with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Douglas K. Marks more than expected).
Fields of papers citing papers by Douglas K. Marks
This network shows the impact of papers produced by Douglas K. Marks. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Douglas K. Marks. The network helps show where Douglas K. Marks may publish in the future.
Co-authors
The 25 scholars most cited alongside Douglas K. Marks, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 28 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2011 | 55 | |
| 2 | 2023 | 41 | |
| 3 | 2018 | 37 | |
| 4 | 2018 | 29 | |
| 5 | 2021 | 22 | |
| 6 | 2020 | 22 | |
| 7 | 2018 | 19 | |
| 8 | 2020 | 17 | |
| 9 | 2019 | 17 | |
| 10 | 2017 | 13 | |
| 11 | 2022 | 11 | |
| 12 | 2023 | 7 | |
| 13 | 2020 | 5 | |
| 14 | 2023 | 3 | |
| 15 | 2017 | 3 | |
| 16 | 2019 | 2 | |
| 17 | 2021 | 2 | |
| 18 | 2015 | 2 | |
| 19 | 2018 | 2 | |
| 20 | 2018 | 2 |
About Douglas K. Marks
Douglas K. Marks is a scholar working on Oncology, Molecular Biology, Pulmonary and Respiratory Medicine, Immunology and Cancer Research, having authored 28 papers that have together received 316 indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (5 papers), Immunotherapy and Immune Responses (5 papers), CAR-T cell therapy research (3 papers), Hyperglycemia and glycemic control in critically ill and hospitalized patients (2 papers), Cancer Genomics and Diagnostics (2 papers), Ferroptosis and cancer prognosis (2 papers), Metabolism, Diabetes, and Cancer (2 papers) and Advanced Breast Cancer Therapies (2 papers). The work is most often cited by research in Oncology (149 citations), Immunology (66 citations), Pulmonary and Respiratory Medicine (59 citations), Cancer Research (25 citations) and Epidemiology (52 citations). Douglas K. Marks has collaborated with scholars based in United States, Canada and Switzerland. Frequent co-authors include Stephen E. Goldstone, Yvonne M. Saenger, Robyn D. Gartrell, Thomas D. Hart, Basil A. Horst, Bret Taback, Emanuelle M. Rizk, Evan Rosenbaum, Kimberly M. Komatsubara and Shahzad Raza. Their work appears in journals such as Journal of Clinical Oncology, Clinical Cancer Research, Cancer Research, Clinical Breast Cancer and Blood.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.